

Edgar Filing: NOVARTIS AG - Form 6-K

NOVARTIS AG  
Form 6-K  
January 09, 2004

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 or 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934

Report on Form 6-K dated January 9, 2004  
(Commission File No. 1-15024)

-----  
Novartis AG  
(Name of Registrant)

-----  
Lichtstrasse 35  
4056 Basel  
Switzerland  
-----

(Address of Principal Executive Offices)

-----  
Indicate by check mark whether the registrant files or will file annual reports  
under cover of Form 20-F or Form 40-F:

Form 20-F:  Form 40-F:

Indicate by check mark if the registrant is submitting the Form 6-K in paper as  
permitted by Regulation S-T Rule 101(b)(1):

Yes:  No:

Indicate by check mark if the registrant is submitting the Form 6-K in paper as  
permitted by Regulation S-T Rule 101(b)(7):

Yes:  No:

Indicate by check mark whether the registrant by furnishing the information  
contained in this form is also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes:  No:

Enclosure: Invitation to Participate in Novartis' Full Year Results 2003  
Presentation.

Edgar Filing: NOVARTIS AG - Form 6-K

Investor Relations

Novartis International AG  
CH-4002 Basel  
Switzerland

[GRAPHIC OMITTED]

Novartis Corporation  
608 Fifth Avenue  
New York, NY 10020  
USA

-----  
-SAVE THE DATE-  
-----

Novartis' Full Year Results 2003 Presentation

to be held

in Zurich, Switzerland

on

Thursday, January 22, 2004

Door opening at 13.30, start at 14:00

# # #

-----  
Novartis Global Investor Relations  
-----

Karen J. Huebscher, Ph.D. +41 61 324 84 33  
-----

International office

Nafida Bendali +41 61 324 35 14

Katharina Furrer +41 61 324 53 16

Silke Zentner +41 61 324 86 12

e-mail: investor.relations@group.novartis.com

Fax: +41 61 324 84 44  
www.novartis.com  
-----

North American office

Alex Kelly +1 212 830 24 45

John Menditto +1 212 830 24 44

Sabine Moravi +1 212 830 24 56

Jill Pozarek +1 212 830 24 45

e-mail: investor.relations@group.novarti

Fax: +1 212 830 24 05  
www.novartis.com  
-----

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,

Edgar Filing: NOVARTIS AG - Form 6-K

Novartis AG has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NOVARTIS AG

Date: January 9, 2004

By: /s/ MALCOLM CHEETHAM

-----  
Name: Malcolm Cheetham  
Title: Head Group Financial Reporting  
and Accounting